Fetal Base Excess MoM Analysis for Neurological Injury Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing fetal health and predicting neurological injury during labor, such as the American College of Obstetricians and Gynecologists' Category System and electronic fetal monitoring, are inadequate, missing significant cases of cerebral palsy and leading to unnecessary cesarean deliveries without effectively reducing severe complications.
Innovation Solution
The method involves analyzing fetal blood for base excess (BE) values during labor, determining multiples of the median (MoM) BE values, and intervening with therapeutic measures when risk is indicated to reduce neurological injury, combined with the Fetal Reserve Index (FRI) to assess fetal risk using various clinical parameters.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If the ACOG Category System is used to assess fetal health, then the system is simple to operate, but it has low measurement precision and misses up to 50% of cerebral palsy cases
Solution Approach 1:
The patent transforms the subjective ACOG Category System into an objective quantitative system by measuring base excess (BE) values and calculating multiples of the median (MoM). This parameter change from categorical assessment to numerical measurement resolves the contradiction by providing both ease of operation through standardized calculations and high measurement precision through objective biochemical markers that correctly identify fetal neurological injury risk.
2Loss of time
If electronic fetal monitoring (EFM) is used to identify asphyxiated fetuses, then intervention can be timed, but the interpretation is subjective and experts disagree on pattern significance
Solution Approach 1:
The patent replaces the mechanical/subjective interpretation of EFM patterns with a biochemical measurement system that directly assesses fetal metabolic status through base excess values. This substitution eliminates subjective interpretation variability while maintaining timely intervention capability, as BE values provide objective evidence of fetal acidosis and neurological injury risk that can be acted upon immediately.
3Reliability
If ACOG Category III criteria are used to trigger delivery, then the positive predictive value for damage is high, but the false negative rate is very high with 50% of serious cases missed
Solution Approach 1:
The patent introduces base excess measurement as an intermediary biomarker that directly reflects fetal metabolic status and neurological injury risk. This intermediary provides a more reliable and precise indicator than ACOG Category III criteria, as BE values continuously track fetal acidosis development and identify at-risk fetuses before irreversible damage occurs, eliminating the high false negative rate while maintaining high positive predictive value.
4Adaptability or versatility
If ACOG Category II criteria are used for screening, then up to 75% of all patients are classified as having concern, but this renders the category useless as a screening test due to low specificity
Solution Approach 1:
The patent applies local quality by focusing on specific biochemical parameters (base excess values and MoM calculations) rather than using broad categorical assessments. This approach improves measurement precision by identifying the specific metabolic changes that indicate fetal neurological injury risk, allowing accurate differentiation between true positive cases and normal variations without over-classifying patients as concerning.
Data Source
AI summary
Methods and apparatus for reducing the risk of neurological injury to a human fetus during labor and before are disclosed. Such a method, according to one embodiment, includes the steps of: (1) identifying during labor the risk of neurological injury to a fetus by: at a first period in time during the first stage of labor, conducting an analysis of fetal blood to determine at least a first base excess (BE) value for the fetus; (2) determining a multiple of the median for the BE value at the first period in time by dividing the BE value by the median BE value of a dataset comprising a population of fetal BE values established at the same period in time during the first stage of labor as the first period, wherein a risk of neurological injury to the fetus is indicated when the BE value is a predefined multiple of the median BE value; and (3) treating the fetus for which the risk of neurological injury is indicated by the identification step, wherein the treatment step comprises intervening in labor to reduce or eliminate the risk of neurological injury to the fetus through any conventional therapeutic measures.